Aβ oligomers - A decade of discovery

Journal of Neurochemistry

Volumn 101, Issue 5, 2007, Pages 1172-1184

  Walsh, Dominic M ^a   Selkoe, Dennis J ^b  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Aggregation; Alzheimer's disease; Amyloid protein; Oligomerization; Synaptic dysfunction

Indexed keywords

AMYLOID BETA PROTEIN; OLIGOMER;

ALZHEIMER DISEASE; BRAIN; COMPREHENSION; HUMAN; KNOWLEDGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; REVIEW; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; HUMANS; MALE; PROTEIN STRUCTURE, SECONDARY;

MUS MUSCULUS;

EID: 34248190279     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2006.04426.x     Document Type: Review

References (145)

1. Adlard P. A., Perreau V. M., Pop V. Cotman C. W. (2005) Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease. J. Neurosci. 25, 4217 4221.
2. Ashe K. H. (2005) Mechanisms of memory loss in Abeta and tau mouse models. Biochem. Soc. Trans. 33, 591 594.
3. Barghorn S., Nimmrich V., Striebinger A. et al. (2005) Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. J. Neurochem. 95, 834 847.
4. Bentahir M., Nyabi O., Verhamme J., Tolia A., Horre K., Wiltfang J., Esselmann H. De Strooper B. (2006) Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J. Neurochem. 96, 732 742.
5. Burdick D., Soreghan B., Kwon M., Kosmoski J., Knauer M., Henschen A., Yates J., Cotman C. Glabe C. (1992) Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs. J. Biol. Chem. 267, 546 554.
6. Busciglio J., Lorenzo A. Yankner B. (1992) Methological variables in the assessment of beta-amyloid neurotoxicity. Neurobiol. Aging 13, 609 612.
7. Cai X.-D., Golde T. E. Younkin S. G. (1993) Release of excess amyloid β protein from a mutant amyloid β protein precursor. Science 259, 514 516.
8. Cai H. B., Wang Y. S., McCarthy D., Wen H. J., Borchelt D. R., Price D. L. Wong P. C. (2001) BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat. Neurosci. 4, 233 234.
9. Castaño E. M., Ghiso J., Prelli F., Gorevic P. D., Migheli A. Frangione B. (1986) In vitro formation of amyloid fibrils from two synthetic peptides of different lengths homologous to Alzheimer's disease β-protein. BBRC 141, 782 789.
10. Chang L., Bakhos L., Wang Z. G., Venton D. L. Klein W. L. (2003) Femtomole immunodetection of synthetic and endogenous amyloid-b oligomers and its application to Alzheimer's disease drug candidate screening. J. Mol. Neurosci. 20, 305 313.
11. Chapman P. F., White G. L., Jones M. W. et al. (1999) Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat. Neurosci. 2, 271 276.
12. Chartier-Harlin M.-C., Crawford F. Houlden H. (1991) Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature 353, 844 846.
13. Citron M., Oltersdorf T., Haass C., McConlogue L., Hung A. Y., Seubert P., Vigo-Pelfrey C., Lieberburg I. Selkoe D. J. (1992) Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases β-protein production. Nature 360, 672 674.
14. Cleary J. P., Walsh D. M., Hofmeister J. J., Shankar G. M., Kuskowski M. A., Selkoe D. J. Ashe K. H. (2005) Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 8, 79 84.
15. Comery T. A., Martone R. L., Aschmies S. et al. (2005) Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 25, 8898 8902.
16. Corder E. H., Saunders A. M., Strittmatter W. J., Schmechel D. E., Gaskell P. C. Jr., Small G. W., Roses A. D., Haines J. L. Pericak-Vance M. A. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921 923.
17. Dahlgren K. N., Manelli A. M., Stine W. B., Jr., Baker L. K., Krafft G. A. LaDu M. J. (2002) Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability. J. Biol. Chem. 277, 32 046 32 053.
18. De Jonghe C., Zehr C., Yager D., Prada C. M., Younkin S., Hendriks L., Van Broeckhoven C. Eckman C. B. (1998) Flemish and Dutch mutations in amyloid beta precursor protein have different effects on amyloid beta secretion. Neurobiol. Dis. 5, 281 286.
19. Demuro A., Mina E., Kayed R., Milton S. C., Parker I. Glabe C. G. (2005) Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J. Biol. Chem. 280, 17 294 17 300.
20. Deshpande A., Mina E., Glabe C. Busciglio J. (2006) Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J. Neurosci. 26, 6011 6018.
21. Dickson D. W., Crystal H. A., Bevona C., Honer W., Vincent I. Davies P. (1995) Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol. Aging 16, 285 298.
22. Dineley K. T., Xia X. F., Bui D., Sweatt J. D. Zheng H. (2002) Accelerated plaque accumulation, associative learning deficits, and up-regulation of alpha 7 nicotinic receptor protein in transgenic mice co-expressing mutant human presenilin 1 and amyloid precursor proteins. J. Biol. Chem. 277, 22 768 22 780.
23. Dodart J. C., Bales K. R., Gannon K. S. et al. (2002) Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 5, 452 457.
24. Dudai Y. (2002) Molecular bases of long-term memories: a question of persistence. Curr. Opin. Neurobiol. 12, 211 216.
25. Enya M., Morishima-Kawashima M., Yoshimura M. et al. (1999) Appearance of sodium dodecyl sulfate-stable amyloid beta-protein (Abeta) dimer in the cortex during aging. Am. J. Path. 154, 271 279.
26. Esler W. P., Kimberly W. T., Ostaszewski B. L., Diehl T. S., Moore C. L., Tsai J. Y., Rahmati T., Xia W. M., Selkoe D. J. Wolfe M. S. (2000) Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1. Nat. Cell Biol. 2, 428 434.
27. Fagan A. M., Watson M., Parsadanian M., Bales K. R., Paul S. M. Holtzman D. M. (2002) Human and murine ApoE markedly alters Abeta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol. Dis. 9, 305 318.
28. Farris W., Schütz S., Cirrito J. et al 2007) Loss of Neprilysin function promotes amyloid plaque formation and precipitates cerebral amyloid angiopathy. J. Neurosci. in press.
29. Funato H., Yoshimura M., Kusui K., Tamaoka A., Ishikawa K., Ohkoshi N., Namekata K., Okeda R. Ihara Y. (1998) Quantitation of amyloid beta-protein (Abeta) in the cortex during aging and in alzheimers-disease. Am. J. Path. 152, 1633 1640.
30. Funato H., Enya M., Yoshimura M., Morishima-Kawashima M. Ihara Y. (1999) Presence of sodium dodecyl sulfate-stable amyloid beta-protein dimers in the hippocampus CA1 not exhibiting neurofibrillary tangle formation. Am. J. Path. 155, 23 28.
31. Gervais F., Paquette J., Morissette C. et al. (2006) Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol. Aging, Epub ahead of print.
32. Geula C., Wu C. K., Saroff D., Lorenzo A., Yuan M. Yankner B. A. (1998) Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity. Nat. Med. 4, 827 831.
33. Gilman S., Koller M., Black R. S. et al. (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64, 1553 1562.
34. Glenner G. G. Wong C. W. (1984) Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. BBRC 120, 885 890.
35. Goate A., Chartier-Harlin M.-C., Mullan M. et al. (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349, 704 706.
36. Goldsbury C. S., Wirtz S., Muller S. A., Sunderji S., Wicki P., Aebi U. Frey P. (2000) Studies on the in vitro assembly of Abeta1-40: implications for the search for a beta fibril formation inhibitors. J. Struct. Biol. 130, 217 231.
37. Gong Y., Chang L., Viola K. L., Lacor P. N., Lambert M. P., Finch C. E., Krafft G. A. Klein W. L. (2003) Alzheimer's disease-affected brain: presence of oligomeric Abeta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl Acad. Sci. U. S. A. 100, 10 417 10 422.
38. Gotz J., Chen F., van Dorpe J. Nitsch R. M. (2001) Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293, 1491 1495.
39. Gu Y., Misonou H., Sato T., Dohmae N., Takio K. Ihara Y. (2001) Distinct intramembrane cleavage of the beta-amyloid precursor protein family resembling gamma-secretase-like cleavage of Notch. J. Biol. Chem. 276, 35 235 35 238.
40. Haass C., Schlossmacher M., Hung A. Y. et al. (1992) Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 359, 322 325.
41. Harper J. D., Lieber C. M. Lansbury P. T., Jr. (1997a) Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid-beta protein. Chem. Biol. 4, 951 959.
42. Harper J. D., Wong S. S., Lieber C. M. Lansbury P. T. Jr. (1997b) Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chem. Biol. 4, 119 125.
43. Harper J. D., Wong S. S., Lieber C. M. Lansbury P. T. (1999) Assembly of Abeta amyloid protofibrils: An in vitro model for a possible early event in Alzheimer's disease. Biochemistry 38, 8972 8980.
44. Hartley D. M., Walsh D. M., Ye C. P., Diehl T., Vasquez S., Vassilev P. M., Teplow D. B. Selkoe D. J. (1999) Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci. 19, 8876 8884.
45. Hepler R. W., Grimm K. M., Nahas D. D. et al. (2006) Solution state characterization of amyloid beta-derived diffusible ligands. Biochemistry 45, 15 157 15 167.
46. Hock C., Konietzko U., Streffer J. R. et al. (2003) Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38, 547 554.
47. Hoshi M., Sato M., Matsumoto S., Noguchi A., Yasutake K., Yoshida N. Sato K. (2003) Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta. Proc. Natl Acad. Sci. U. S. A. 100, 6370 6375.
48. Hsia A. Y., Masliah E., McConlogue L., Yu G. Q., Tatsuno G., Ilu K., Kholodenko D., Malenka R. C., Nicoll R. A. Mucke L. (1999) Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl Acad. Sci. USA 96, 3228 3233.
49. Hsiao K. (1998) Transgenic mice expressing Alzheimer amyloid precursor proteins. Experl. Gerontol. 33, 883 889.
50. Huang S. M., Mouri A., Kokubo H. et al. (2006) Neprilysin-sensitive synapse-associated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function. J. Biol. Chem. 281, 17 941 17 951.
51. Huppert S. S., Ilagan M. X., De Strooper B. Kopan R. (2005) Analysis of Notch function in presomitic mesoderm suggests a gamma-secretase-independent role for presenilins in somite differentiation. Dev. Cell 8, 677 688.
52. Ida N., Hartmann T., Pantel J., Schroder J., Zerfass R., Forstl H., Sandbrink R., Masters C. L. Beyreuther K. (1996) Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J. Biol. Chem. 271, 22 908 22 914.
53. Isaacs A. M., Senn D. B., Yuan M., Shine J. P. Yankner B. A. (2006) Acceleration of amyloid beta-peptide aggregation by physiological concentrations of calcium. J. Biol. Chem. 281, 27 916 27 923.
54. Jacobsen J. S., Wu C. C., Redwine J. M. et al. (2006) Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. U. S. A. 103, 5161 5166.
55. Jarrett J. T., Berger E. P. Lansbury P. T. Jr. (1993) The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32, 4693 4697.
56. Kakuda N., Funamoto S., Yagishita S., Takami M., Osawa S., Dohmae N. Ihara Y. (2006) Equimolar production of amyloid beta-protein and amyloid precursor protein intracellular domain from beta-carboxyl-terminal fragment by gamma-secretase. J. Biol. Chem. 281, 14 776 14 786.
57. Katzman R. (1986) Alzheimer's disease. N. Engl. J. Med. 314, 964 973.
58. Kayed R., Head E., Thompson J. L., McIntire T. M., Milton S. C., Cotman C. W. Glabe C. G. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486 489.
59. Kelly B. L. Ferreira A. (2006) beta-Amyloid-induced dynamin 1 degradation is mediated by N-methyl-d-aspartate receptors in hippocampal neurons. J. Biol. Chem. 281, 28 079 28 089.
60. Kim H. J., Chae S. C., Lee D. K., Chromy B., Lee S. C., Park Y. C., Klein W. L., Krafft G. A. Hong S. T. (2003) Selective neuronal degeneration induced by soluble oligomeric amyloid beta protein. FASEB J. 17, 118 120.
61. Kirschner D. A., Inouye H., Duffy L. K., Sinclair A., Lind M. Selkoe D. J. (1987) Synthetic peptide homologous to beta protein from Alzheimer disease forms amyloid-like fibrils in vitro. Proc. Natl Acad. Sci. U. S. A. 84, 6953 6957.
62. Klyubin I., Walsh D. M., Lemere C. A. et al. (2005) Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat. Med. 11, 556 561.
63. Kopan R. Ilagan M. X. (2004) Gamma-secretase: proteasome of the membrane Nat. Rev. Mol. Cell Biol. 5, 499 504.
64. Kumar-Singh S., Theuns J., Van Broeck B., Pirici D., Vennekens K., Corsmit E., Cruts M., Dermaut B., Wang R. Van Broeckhoven C. (2006) Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. Hum. Mutat. 27, 686 695.
65. Kuo W. L., Gehm B. D. Rosner M. R. (1990) Cloning and expression of the cDNA for a Drosophila insulin-degrading enzyme. Mol. Endocrinol. 4, 1580 1591.
66. Lacor P. N., Buniel M. C., Chang L. et al. (2004) Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J. Neurosci. 24, 10 191 10 200.
67. Lambert M. P., Barlow A. K., Chromy B. A. et al. (1998) Diffusible, nonfribrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl Acad. Sci. U. S. A. 95, 6448 6453.
68. Lambert M. P., Viola K. L., Chromy B. A., Chang L., Morgan T. E., Yu J., Venton D. L., Krafft G. A., Finch C. E. Klein W. L. (2001) Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J. Neurochem. 79, 595 605.
69. Lashuel H. A., Hartley D. M., Balakhaneh D., Aggarwal A., Teichberg S. Callaway D. J. (2002) New class of inhibitors of amyloid-beta fibril formation. Implications for the mechanism of pathogenesis in Alzheimer's disease. J. Biol. Chem. 277, 42 881 42 890.
70. Lazarov O., Robinson J., Tang Y. P., Hairston I. S., Korade-Mirnics Z., Lee V. M., Hersh L. B., Sapolsky R. M., Mirnics K. Sisodia S. S. (2005) Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell 120, 701 713.
71. Leissring M. A., Farris W., Chang A. Y., Walsh D. M., Wu X., Sun X., Frosch M. P. Selkoe D. J. (2003) Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 40, 1087 1093.
72. Lemere C. A., Maier M., Jiang L., Peng Y. Seabrook T. J. (2006) Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans. Rejuvenation Res. 9, 77 84.
73. Lesne S., Koh M. T., Kotilinek L., Kayed R., Glabe C. G., Yang A., Gallagher M. Ashe K. H. (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440, 352 357.
74. Levy E., Carman M. D., Fernandez-Madrid I. J., Power M. D., Lieberburg I., van Duinen S. G., Bots G. T. A. M., Luyendijk W. Frangione B. (1990) Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch-type. Science 248, 1124 1126.
75. Lewis J., Dickson D. W., Lin W. L. et al. (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293, 1487 1491.
76. Li Y.-M., Xu M., Lai M.-T. et al. (2000) Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 405, 689 694.
77. Lue L. F., Kuo Y. M., Roher A. E., Brachova L., Shen Y., Sue L., Beach T., Kurth J. H., Rydel R. E. Rogers J. (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155, 853 862.
78. Maloney M. T., Minamide L. S., Kinley A. W., Boyle J. A. Bamburg J. R. (2005) Beta-secretase-cleaved amyloid precursor protein accumulates at actin inclusions induced in neurons by stress or amyloid beta: a feedforward mechanism for Alzheimer's disease. J. Neurosci. 25, 11 313 11 321.
79. Mann D. M., Yates P. O. Marcyniuk B. (1984) Alzheimer's presenile dementia, senile dementia of Alzheimer type and Down's syndrome in middle age form an age related continuum of pathological changes. Neuropathol. Appl. Neurobiol. 10, 185 207.
80. Masliah E., Hansen L., Adame A., Crews L., Bard F., Lee C., Seubert P., Games D., Kirby L. Schenk D. (2005) Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64, 129 131.
81. Masters C. L., Simms G., Weinman N. A., Multhaup G., McDonald B. L. Beyreuther K. (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl Acad. Sci. U. S. A. 82, 4245 4249.
82. McLaurin J., Kierstead M. E., Brown M. E. et al. (2006) Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat. Med. 12, 801 808.
83. McLean C. A., Cherny R. A., Fraser F. W., Fuller S. J., Smith M. J., Beyreuther K., Bush A. I. Masters C. L. (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46, 860 866.
84. Moechars D., Dewachter I., Lorent K. et al. (1999) Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J. Biol. Chem. 274, 6483 6492.
85. Morishima-Kawashima M. Ihara Y. (1998) The presence of amyloid beta-protein in the detergent-insoluble membrane compartment of human neuroblastoma cells. Biochem 37, 15 247 15 253.
86. Motte J. Williams R. S. (1989) Age-related changes in the density and morphology of plaques and neurofibrillary tangles in Down syndrome brain. Acta Neuropathol. 77, 535 546.
87. Mucke L., Masliah E., Yu G. Q., Mallory M., Rockenstein E. M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K. McConlogue L. (2000) High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20, 4050 4058.
88. Mueller-Steiner S., Zhou Y., Arai H. et al. (2006) Anti-amyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. Neuron 51, 703 714.
89. Nicoll J. A., Wilkinson D., Holmes C., Steart P., Markham H. Weller R. O. (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 9, 448 452.
90. Nilsberth C., Westlind-Danielsson A., Eckman C. B. et al. (2001) The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat. Neurosci. 4, 887 893.
91. Nybo M., Svehag S. E. Holm Nielsen E. (1999) An ultrastructural study of amyloid intermediates in A beta 1-42 fibrillogenesis. Scand. J. Immunol. 49, 219 223.
92. O'Hare E., Levine A. S., Semotuk M. T., Tierney K. J., Shephard R. A., Grace M. K. Cleary J. (1996) Utilization of a novel model of food reinforced behavior involving neuropeptide Y, insulin, 2-deoxy-d-glucose and naloxone. Behav. Pharmacol. 7, 742 753.
93. Oda T., Wals P., Osterburg H. H. et al. (1995) Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (Abeta 1-42) and forms slowly sedimenting Abeta complexes that cause oxidative stress. Exp. Neurol. 136, 22 31.
94. Oddo S., Caccamo A., Shepherd J. D., Murphy M. P., Golde T. E., Kayed R., Metherate R., Mattson M. P., Akbari Y. LaFerla F. M. (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39, 409 421.
95. Olson M. I. Shaw C. M. (1969) Presenile dementia and Alzheimer's disease in mongolism. Brain 92, 147 156.
96. Pike C. J., Walencewicz A. J., Glabe C. G. Cotman C. W. (1991) In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 563, 311 314.
97. Podlisny M. B., Ostaszewski B. L., Squazzo S. L., Koo E. H., Rydel R. E., Teplow D. B. Selkoe D. J. (1995) Aggregation of secreted amyloid β-protein into SDS-stable oligomers in cell culture. J. Biol. Chem. 270, 9564 9570.
98. Prasher V. P., Farrer M. J., Kessling A. M., Fisher E. M., West R. J., Barber P. C. Butler A. C. (1998) Molecular mapping of Alzheimer-type dementia in Down's syndrome. Ann. Neurol. 43, 380 383.
99. Rebeck G. W., Reiter J. S., Strickland D. K. Hyman B. T. (1993) Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 11, 575 580.
100. Richardson R. L., Kim E. M., Shephard R. A., Gardiner T., Cleary J. O'Hare E. (2002) Behavioural and histopathological analyses of ibuprofen treatment on the effect of aggregated Abeta (1-42) injections in the rat. Brain Res. 954, 1 10.
101. Roher A. E., Chaney M. O., Kuo Y.-M. et al. (1996) Morphology and toxicity of Abeta(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J. Biol. Chem. 271, 20 631 20 635.
102. Rovelet-Lecrux A., Hannequin D., Raux G. et al. (2006) APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat. Genet. 38, 24 26.
103. Santacruz K., Lewis J., Spires T. et al. (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476 481.
104. Saunders A. M., Schmader K., Breitner J. C. S. et al. (1993) Apolipoprotein E ε4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases. Lancet 342, 710 711.
105. Schenk D. B., Seubert P., Grundman M. Black R. (2005) Abeta immunotherapy: lessons learned for potential treatment of Alzheimer's disease. Neurodegener Dis. 2, 255 260.
106. Schroeter E. H., Ilagan M. X., Brunkan A. L. et al. (2003) A presenilin dimer at the core of the gamma-secretase enzyme: insights from parallel analysis of Notch 1 and APP proteolysis. Proc. Natl Acad. Sci. U. S. A. 100, 13 075 13 080.
107. Selkoe D. J. Schenk D. (2003) Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu. Rev. Pharmacol. Toxicol. 43, 545 584.
108. Selkoe D. J., Abraham C. R., Podlisny M. B. Duffy L. K. (1986) Isolation of low-molecular-weight proteins from amyloid plaque fibers in Alzheimer's disease. J. Neurochem. 146, 1820 1834.
109. Seubert P., Vigo-Pelfrey C., Esch F. et al. (1992) Isolation and quantitation of soluble Alzheimer's β-peptide from biological fluids. Nature 359, 325 327.
110. Shankar G. M., Townsend M., Walsh D. M., Selkoe D. J. Sabatini B. L. (2007) Natural oligomers of the Alzheimer amyloid beta-protein induce hippocampal synapse loss but can be neutralized by antibodies and small molecules. J. Neurosci. in press.
111. Shoji M., Golde T. E., Ghiso J. et al. (1992) Production of the Alzheimer amyloid β protein by normal proteolytic processing. Science 258, 126 129.
112. Siemers E. R., Quinn J. F., Kaye J. et al. (2006) Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 66, 602 604.
113. Snyder S. W., Ladror U. S., Wade W. S., Wang G. T., Barrett L. W., Matayoski E. D., Huffaker H. J., Krafft G. Holzman T. (1994) Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths. Biophys. J. 67, 1216 1228.
114. Snyder E. M., Nong Y., Almeida C. G. et al. (2005) Regulation of NMDA receptor trafficking by amyloid-beta. Nat. Neurosci. 8, 1051 1058.
115. Stenh C., Englund H., Lord A., Johansson A. S., Almeida C. G., Gellerfors P., Greengard P., Gouras G. K., Lannfelt L. Nilsson L. N. (2005) Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay. Ann. Neurol. 58, 147 150.
116. Strittmatter W. J., Weisgraber K. H., Huand D., Dong L.-M., Salvesen G. S., Pericak-Vance M., Schmechel D., Saunder A. M., Goldgaber D. Roses A. D. (1993) Binding of human apolipoprotein E to synthetic amyloid β peptide: isoform specific effects and implications for late-onset Alzheimer disease. Proc. Natl Acad. Sci. U. S. A. 90, 8098 8102.
117. Suzuki N., Cheung T. T., Cai X.-D., Odaka A., Otvos L. Jr., Eckman C., Golde T. E. Younkin S. G. (1994) An increased percentage of long amyloid β protein secreted by familial amyloid beta-protein precursor (betaAPP717) mutants. Science 264, 1336 1340.
118. Tamagno E., Bardini P., Guglielmotto M., Danni O. Tabaton M. (2006) The various aggregation states of beta-amyloid 1-42 mediate different effects on oxidative stress, neurodegeneration, and BACE-1 expression. Free Radic. Biol. Med. 41, 202 212.
119. Terry R. D., Masliah E., Salmon D. P., Butters N., DeTeresa R., Hill R., Hansen L. A. Katzman R. (1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Annal. Neurol. 30, 572 580.
120. Townsend M., Shankar G. M., Mehta T., Walsh D. M. Selkoe D. J. (2006a) Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J. Physiol. 572, 477 492.
121. Townsend M., Cleary J. P., Mehta T., Hofmeister J., Lesne S., O'Hare E., Walsh D. Selkoe D. (2006b) Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Ann. Neurol. 60, 668 676.
122. Van Nostrand W. E., Melchor J. P., Cho H. S., Greenberg S. M. Rebeck G. W. (2001) Pathogenic effects of D23N Iowa mutant amyloid beta-protein. J. Biol. Chem. 276, 32 860 32 866.
123. Vassar R., Bennett B. D., Babu-Khan S. et al. (1999) Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735 741.
124. Vigo-Pelfrey C., Lee D., Keim P. S., Lieberburg I. Schenk D. (1993) Characterization of beta-amyloid peptide from human cerebrospinal fluid. J. Neurochem. 61, 1965 1968.
125. Walsh D. M., Lomakin A., Benedek G. B., Maggio J. E., Condron M. M. Teplow D. B. (1997) Amyloid β-protein fibrillogenesis: Detection of a protofibrillar intermediate. J. Biol. Chem. 272, 22 364 22 374.
126. Walsh D. M., Hartley D. M., Kusumoto Y., Fezoui Y., Condron M. M., Lomakin A., Benedek G. B., Selkoe D. J. Teplow D. B. (1999) Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J. Biol. Chem. 274, 25 945 25 952.
127. Walsh D. M., Tseng B. P., Rydel R. E., Podlisny M. B. Selkoe D. J. (2000) The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry 39, 10 831 10 839.
128. Walsh D., Klyubin I., Fadeeva J., William K., Cullen W., Anwyl R., Wolfe M., Rowan M. Selkoe D. (2002a) Naturally secreted oligomers of the Alzheimer amyloid beta-protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535 539.
129. Walsh D. M., Klyubin I., Fadeeva J. V., Rowan M. J. Selkoe D. J. (2002b) Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem. Soc. Trans. 30, 552 557.
130. Walsh D. M., Hartley D. M. Selkoe D. J. (2003) The many faces of Abeta: structures and activity. Curr. Med. Chem - Immun., Endoc. Metab. Agents 3, 277 291.
131. Walsh D. M., Townsend M., Podlisny M. B., Shankar G. M., Fadeeva J. V., Agnaf O. E., Hartley D. M. Selkoe D. J. (2005) Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. J. Neurosci. 25, 2455 2462.
132. Wang J., Dickson D. W., Trojanowski J. Q. Lee V. M. (1999) The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp. Neurol. 158, 328 337.
133. Wang H. W., Pasternak J. F., Kuo H. et al. (2002) Soluble oligomers of beta-amyloid(1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 924, 133 140.
134. Weidemann A., Konig G., Bunke D., Fischer P., Salbaum J. M., Masters C. L. Beyreuther K. (1989) Identification, biogenesis and localization of precursors of Alzheimer's disease A4 amyloid protein. Cell 57, 115 126.
135. Weidemann A., Eggert S., Reinhard F. B., Vogel M., Paliga K., Baier G., Masters C. L., Beyreuther K. Evin G. (2002) A novel epsilon-cleavage within the transmembrane domain of the Alzheimer amyloid precursor protein demonstrates homology with Notch processing. Biochemistry 41, 2825 2835.
136. Westerman M. A., Cooper-Blacketer D., Mariash A., Kotilinek L., Kawarabayashi T., Younkin L. H., Carlson G. A., Younkin S. G. Ashe K. H. (2002) The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 22, 1858 1867.
137. Whalen B. M., Selkoe D. J. Hartley D. M. (2005) Small non-fibrillar assemblies of amyloid beta-protein bearing the Arctic mutation induce rapid neuritic degeneration. Neurobiol. Dis. 20, 254 266.
138. White A. R., Reyes R., Mercer J. F., Camakaris J., Zheng H., Bush A. I., Multhaup G., Beyreuther K., Masters C. L. Cappai R. (1999) Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice. Brain Res. 842, 439 444.
139. Wisniewski T., Ghiso J. Frangione B. (1991) Peptides homologous to the amyloid protein of Alzheimer's disease containing a glutamine for glutamic acid substitution have accelerated amyloid fibril formation. BBRC 179, 1247 1254.
140. Wolfe M. S., Xia W., Ostaszewski B. L., Diehl T. S., Kimberly W. T. Selkoe D. J. (1999) Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity. Nature 398, 513 517.
141. Wu C. C., Chawla F., Games D., Rydel R. E., Freedman S., Schenk D., Young W. G., Morrison J. H. Bloom F. E. (2004) Selective vulnerability of dentate granule cells prior to amyloid deposition in PDAPP mice: digital morphometric analyses. Proc. Natl. Acad. Sci. USA 101, 7141 7146.
142. Xia W., Zhang J., Kholodenko D., Citron M, Podlisny M. B., Teplow D. B., Haass C., Seubert P., Koo E. H. Selkoe D. J. (1997) Enhanced production and oligomerization of the 42-residue amyloid beta-protein by Chinese hamster ovary cells stably expressing mutant presenilins. J. Biol. Chem. 272, 7977 7982.
143. Ye C. P., Selkoe D. J. Hartley D. M. (2003) Protofibrils of amyloid beta-protein inhibit specific K+ currents in neocortical cultures. Neurobiol. Dis. 13, 177 190.
144. Zhao G., Mao G., Tan J., Dong Y., Cui M. Z., Kim S. H. Xu X. (2004) Identification of a new presenilin-dependent zeta-cleavage site within the transmembrane domain of amyloid precursor protein. J. Biol. Chem. 279, 50 647 50 650.
145. Zhao L., Ma Q. L., Calon F. et al. (2006) Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease. Nat. Neurosci. 9, 234 242.